Literature DB >> 17469937

Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.

Scott M Hyman1, Helen Fox, Kwang-Ik A Hong, Cheryl Doebrick, Rajita Sinha.   

Abstract

BACKGROUND: Naltrexone is a nonaddictive medication that blocks the euphoric effects of opioids. However, naltrexone treatment is associated with high rates of noncompliance and opioid relapse, possibly because it does not reduce stress and protracted withdrawal symptoms during early recovery. Prior clinical and preclinical research has indicated that both stress and drug-cue-related arousal response is associated with craving and vulnerability to relapse in a range of drug-using populations. AIMS: To examine opioid craving and the subjective and cardiovascular response to stress and drug cues in naltrexone-treated opioid abusers.
METHOD: Eleven men and three women engaged in naltrexone treatment for opioid dependence. They were exposed to personalized stress, drug-cue, and neutral-relaxing imagery in a single laboratory session. Subjective (craving, emotion) and cardiovascular (heart rate, systolic blood pressure, and diastolic blood pressure) measures were assessed.
RESULTS: Stress and drug-cue-related imagery significantly increased opioid craving, anxiety, and negative emotions and significantly decreased positive emotions compared to neutral imagery. Selective emotional responses were greater in the stress condition than in the drug-cue condition. Only stress-related imagery was associated with an increased cardiovascular response.
CONCLUSIONS: Naltrexone-treated opioid abusers demonstrate vulnerability to stress and drug-cue-induced craving and arousal responses that may contribute to the high rates of noncompliance and relapse among opioid-dependent individuals undergoing naltrexone treatment. Pharmacological and behavioral interventions that specifically target the negative affectivity that co-occurs with drug-cue and stress-induced craving could be of benefit in improving naltrexone treatment outcomes in opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17469937      PMCID: PMC2392893          DOI: 10.1037/1064-1297.15.2.134

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  45 in total

1.  Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude.

Authors:  Kathleen M Carroll; Rajita Sinha; Charla Nich; Theresa Babuscio; Bruce J Rounsaville
Journal:  Exp Clin Psychopharmacol       Date:  2002-02       Impact factor: 3.157

2.  Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons.

Authors:  Y Shaham; D Highfield; J Delfs; S Leung; J Stewart
Journal:  Eur J Neurosci       Date:  2000-01       Impact factor: 3.386

Review 3.  Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures.

Authors:  N K Mello; S S Negus
Journal:  Neuropsychopharmacology       Date:  1996-06       Impact factor: 7.853

4.  The effects of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up.

Authors:  L E Carlson; Z Ursuliak; E Goodey; M Angen; M Speca
Journal:  Support Care Cancer       Date:  2001-03       Impact factor: 3.603

5.  Psychological stress, drug-related cues and cocaine craving.

Authors:  R Sinha; T Fuse; L R Aubin; S S O'Malley
Journal:  Psychopharmacology (Berl)       Date:  2000-10       Impact factor: 4.530

Review 6.  How does stress increase risk of drug abuse and relapse?

Authors:  R Sinha
Journal:  Psychopharmacology (Berl)       Date:  2001-10-26       Impact factor: 4.530

7.  Repeated lofexidine treatment attenuates stress-induced, but not drug cues-induced reinstatement of a heroin-cocaine mixture (speedball) seeking in rats.

Authors:  D Highfield; J Yap; J W Grimm; U Shalev; Y Shaham
Journal:  Neuropsychopharmacology       Date:  2001-09       Impact factor: 7.853

8.  Lofexidine versus clonidine in rapid opiate detoxification.

Authors:  G Gerra; A Zaimovic; F Giusti; C Di Gennaro; U Zambelli; S Gardini; R Delsignore
Journal:  J Subst Abuse Treat       Date:  2001-07

9.  Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala.

Authors:  Francesco Leri; Joseph Flores; Demetra Rodaros; Jane Stewart
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

10.  Heroin self-administration under a second-order schedule of reinforcement: acquisition and maintenance of heroin-seeking behaviour in rats.

Authors:  H L Alderson; T W Robbins; B J Everitt
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

View more
  66 in total

1.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

2.  Inhibitory transmission in the bed nucleus of the stria terminalis in male and female mice following morphine withdrawal.

Authors:  Brennon R Luster; Elizabeth S Cogan; Karl T Schmidt; Dipanwita Pati; Melanie M Pina; Kedar Dange; Zoé A McElligott
Journal:  Addict Biol       Date:  2019-04-09       Impact factor: 4.280

Review 3.  Translational and reverse translational research on the role of stress in drug craving and relapse.

Authors:  Rajita Sinha; Yavin Shaham; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2011-04-15       Impact factor: 4.530

Review 4.  Making a bad thing worse: adverse effects of stress on drug addiction.

Authors:  Jessica N Cleck; Julie A Blendy
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

5.  Stress enhances retrieval of drug-related memories in abstinent heroin addicts.

Authors:  Li-Yan Zhao; Jie Shi; Xiao-Li Zhang; David H Epstein; Xiang-Yang Zhang; Yu Liu; Thomas R Kosten; Lin Lu
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

6.  Neural stress reactivity relates to smoking outcomes and differentiates between mindfulness and cognitive-behavioral treatments.

Authors:  Hedy Kober; Judson A Brewer; Keri L Height; Rajita Sinha
Journal:  Neuroimage       Date:  2016-09-28       Impact factor: 6.556

Review 7.  Chronic stress, drug use, and vulnerability to addiction.

Authors:  Rajita Sinha
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

8.  Divergent behavioral responses in protracted opioid withdrawal in male and female C57BL/6J mice.

Authors:  Isabel M Bravo; Brennon R Luster; Meghan E Flanigan; Patric J Perez; Elizabeth S Cogan; Karl T Schmidt; Zoe A McElligott
Journal:  Eur J Neurosci       Date:  2019-10-06       Impact factor: 3.386

9.  Behavioral strategies to reduce stress reactivity in opioid use disorder: Study design.

Authors:  R Kathryn McHugh; Minh D Nguyen; Garrett M Fitzmaurice; Daniel G Dillon
Journal:  Health Psychol       Date:  2020-09       Impact factor: 4.267

10.  The association between negative affect and prescription opioid misuse in patients with chronic pain: the mediating role of opioid craving.

Authors:  Marc O Martel; Andrew J Dolman; Robert R Edwards; Robert N Jamison; Ajay D Wasan
Journal:  J Pain       Date:  2013-10-12       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.